Shikimic acid is a precursor for:
In the pharmaceutical industry, shikimic acid from the Chinese star anise is used as a base material for production of Tamiflu (oseltamivir). Although shikimic acid is present in most autotrophic organisms, it is a biosynthetic intermediate and generally found in very low concentrations. The low isolation yield of shikimic acid from the Chinese star anise is blamed for the 2005 shortage of oseltamivir. Shikimic acid can also be extracted from the seeds of the sweetgum fruit, which is abundant in North America, in yields of around 1.5%, so just 4 kg of sweetgum seeds are enough for fourteen packages of Tamiflu. By comparison star anise has been reported to yield 3 to 7% shikimic acid. Recently biosynthetic pathways in E. coli have been enhanced to allow the organism to accumulate enough material to be used commercially.
Phosphoenolpyruvate and erythrose-4-phosphate react to form 3-deoxy-D-arabinoheptulosonate-7-phosphate (DAHP), in a reaction catalysed by the enzyme DAHP synthase. DAHP is then transformed to 3-dehydroquinate(DHQ), in a reaction catalysed by DHQ synthase. Although this reaction requires NAD as a cofactor, the enzymic mechanism regenerates it, resulting in the net use of no NAD (note that diagram is incorrect).
DHQ is dehydrated to 3-dehydroshikimate by the enzyme dehydroquinase, which is reduced by to shikimic acid by the enzyme shikimate dehydrogenase, which uses NADPH as a cofactor.